Targeting replication stress in cancer therapy

AABA da Costa, D Chowdhury, GI Shapiro… - Nature reviews Drug …, 2023 - nature.com
Replication stress is a major cause of genomic instability and a crucial vulnerability of
cancer cells. This vulnerability can be therapeutically targeted by inhibiting kinases that …

A retrospective-prospective review of Suzuki–Miyaura reaction: From cross-coupling reaction to pharmaceutical industry applications

M Farhang, AR Akbarzadeh, M Rabbani, AM Ghadiri - Polyhedron, 2022 - Elsevier
Carbon-carbon coupling is the most important reaction in chemical, academia, and industrial
scales. The Suzuki-Miyaura coupling is a cross-coupling reaction in which the coupling …

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

B Besse, E Pons-Tostivint, K Park, S Hartl, PM Forde… - Nature medicine, 2024 - nature.com
For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable
molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L) 1 …

An ATR-PrimPol pathway confers tolerance to oncogenic KRAS-induced and heterochromatin-associated replication stress

T Igarashi, M Mazevet, T Yasuhara, K Yano… - Nature …, 2023 - nature.com
Activation of the KRAS oncogene is a source of replication stress, but how this stress is
generated and how it is tolerated by cancer cells remain poorly understood. Here we show …

[HTML][HTML] Oncology phase I trial design and conduct: time for a change-MDICT Guidelines 2022

D Araujo, A Greystoke, S Bates, A Bayle, E Calvo… - Annals of …, 2023 - Elsevier
Highlights•Recent experience with targeted anticancer drugs and immunotherapies suggest
the traditional approach of using the maximal tolerated dose (MTD) is not ideal.•Project …

The cost of quantum yield

JR Swierk - Organic Process Research & Development, 2023 - ACS Publications
The quantum yield (QY) of a photocatalytic reaction significantly influences its performance,
as reactions with low QYs require more intense light sources and longer illumination times to …

Therapeutic targeting of DNA damage response in cancer

W Choi, ES Lee - International journal of molecular sciences, 2022 - mdpi.com
DNA damage response (DDR) is critical to ensure genome stability, and defects in this
signaling pathway are highly associated with carcinogenesis and tumor progression …

[HTML][HTML] The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy

FP Vendetti, P Pandya, DA Clump… - JCI insight, 2023 - ncbi.nlm.nih.gov
Inhibitors of the DNA damage signaling kinase ATR increase tumor cell killing by
chemotherapies that target DNA replication forks but also kill rapidly proliferating immune …

ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer

H Taniguchi, S Chakraborty, N Takahashi… - Science …, 2024 - science.org
Patients with small-cell lung cancer (SCLC) have poor prognosis and typically experience
only transient benefits from combined immune checkpoint blockade (ICB) and …

Targeting the DNA damage response pathways and replication stress in colorectal cancer

E Durinikova, NM Reilly, K Buzo, E Mariella… - Clinical Cancer …, 2022 - AACR
Purpose: Genomic instability is a hallmark of cancer and targeting DNA damage response
(DDR) is emerging as a promising therapeutic strategy in different solid tumors. The …